This study explores the prognostic impact of differently expressed piRNAs on DLBCL, we developed a more accurate prognostic model for DLBCL by combining traditional clinical indicators (IPI/NCCN-IPI), and elucidates how piRNAs contribute to doxorubicin resistance and the underlying signaling pathways through experiments.